How many Omicron mutations can sotrovimab neutralise?

Question

Accepted Answer

Sotrovimab Demonstrates Efficacy Against All Identified Omicron Spike Protein Mutations

New early-stage study data indicates that sotrovimab, a Covid-19 therapy developed by GSK and its partner Vir Biotechnology, is effective against all 37 identified mutations in the spike protein of the Omicron variant. This finding is based on laboratory tests using engineered pseudoviruses that incorporate key mutations from various variants of concern. The companies have stated that these pre-clinical data suggest sotrovimab retains its potential efficacy against the Omicron variant, along with other variants previously designated by the World Health Organisation.
Efficacy Against Identified Mutations

The pre-clinical data specifically show that sotrovimab effectively neutralises all 37 mutations that have been identified to date within the spike protein of the SARS-CoV-2 virus, including those characteristic of the Omicron variant. This testing involved creating pseudoviruses designed to mimic the mutations found in concerning variants.
Basis of the Findings

These conclusions stem from early-stage studies conducted by GSK and Vir Biotechnology. The companies engineered pseudoviruses that contained major coronavirus mutations observed across emerging variants. Subsequent laboratory tests were performed to assess the vulnerability of these pseudoviruses to sotrovimab treatment.
Ongoing Research and Publication Status

While the recent data suggests sotrovimab's effectiveness, it is important to note that these findings are from early-stage studies. The data has not yet been published in a peer-reviewed medical journal, which is a standard process for validating scientific research in the medical field.
Potential Therapeutic Application

GSK's Chief Scientific Officer, Hal Barron, highlighted that these pre-clinical findings demonstrate the potential for their monoclonal antibody therapy to be effective against the Omicron variant. He further stated that this potential extends to all other variants of concern that have been defined by the World Health Organisation up to this point.

Reading history

Hide →

This history is cleared when the page is closed.

How many Omicron mutations can sotrovimab neutralise?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends